Atomo Diagnostics (ASX:AT1) secured an agreement to supply its HIV self-test kit to UK-based Newfoundland Diagnostics, valued at AU$5.4 million over five years, according to a Tuesday filing with the Australian bourse.
The agreement, running until June 30, 2030, grants Newfoundland exclusive distribution rights for the company's tests in the UK and non-exclusive rights for the EU and Colombia, the filing said.
Atomo Diagnostics shares rose nearly 6% in midday trade Tuesday.
Price (AUD): $0.02, Change: $+0.0010, Percent Change: +5.56%
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。